Lexicon Pharmaceuticals tops Q4 estimates as losses narrow

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported fourth-quarter financial results on Thursday that exceeded Wall Street expectations, driven by reduced operating expenses and licensing revenue.

The Woodlands, Texas-based drugmaker posted a net loss of $15.5 million, or 4 cents per share, significantly better than the 7-cent loss per share projected by analysts surveyed by Zacks Investment Research.

Quarterly revenue reached $5.5 million, primarily supported by net sales of its heart failure medication, INPEFA, and milestone-related licensing income.

For the full year, the company reported a total loss of $50.3 million, or 14 cents per share, on revenue of $49.8 million.

Lexicon ended 2025 with a cash position of approximately $125.2 million, bolstered by a strategic repositioning that cut annual selling and administrative costs by more than 70% compared to the previous year.